Cardiff Oncology Inc share price logo

Cardiff Oncology Inc

NASDAQ: CRDF

Small Cap

$1.67

+0.03

(+1.52%)

Live

as on

Cardiff Oncology Inc Stock Performance

as on May 14, 2026 at 4:13 am IST

  • Day's Low

    Day's High

    $1.64
    $1.71
    downward going graph

    1.80%

    Downside

    2.40%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.48
    $4.56
    downward going graph

    11.38%

    Downside

    172.75%

    Upside

    downward going graph

Cardiff Oncology Inc share price movements today

Previous Close
$1.64
Open
$1.66
Volume
463.6K
Day's Low - High
$1.64 - $1.71
52 Week Low - High
$1.48 - $4.56

Cardiff Oncology Inc Historical Returns

1 Month Return
+ 3.14 %
3 Month Return
+ 2.5 %
1 Year Return
-39.71 %
3 Year Return
-2.96 %
5 Year Return
-80.68 %

Cardiff Oncology Inc Stock Fundamentals & Key Indicators

Check Cardiff Oncology Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$111.4M

EPS (TTM)

-0.518

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-48.6M

Revenue (TTM)

593.0K

Profit Margin

0.00%

Return On Equity TTM

-71.45%

Cardiff Oncology Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cardiff Oncology Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$111.4M-80.68%NA0.00%
BUY$38.0B119.7%71.3912.55%
NA$32.7BNA71.448.94%
BUY$110.4B109.14%25.8435.51%
BUY$74.7B39.88%17.3929.65%

Stock Returns calculator for Cardiff Oncology Inc Stock including INR - Dollar returns

The Cardiff Oncology Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cardiff Oncology Inc investment value today

Current value as on today

₹68,907

Returns

-₹31,093

(-31.09%)

Returns from Cardiff Oncology Inc Stock

-₹38,603 (-38.6%)

Dollar Impact

₹7,510 (+7.51%)

Analyst Recommendation on Cardiff Oncology Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Cardiff Oncology Inc. Average target price of $7.75

Cardiff Oncology Inc Share Price Target

Get share price movements and forecasts by analysts on Cardiff Oncology Inc.

What analysts predicted

78.45%UPSIDE

Target Price

$7.75

Current Price

$1.67

Analyzed by

10 Analysts

Target

$7.75

Cardiff Oncology Inc target price $7.75, a slight upside of 78.45% compared to current price of $1.67. According to 10 analysts rating.

Indian Investors' Interest in Cardiff Oncology Inc Stock

Search interest for Cardiff Oncology Inc Stock has increased by 64% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:64% versus previous 30 day period

Cardiff Oncology Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
-9
0
0
-11
0
0
Operating Income
-10
-10
-10
-12
-12
-12
-14
-14
-11
-7
EBITDA
-10
-10
-10
-12
-12
-12
-14
-14
-10
-6
Interest Expense
-
0
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-9
-9
-10
-11
-11
-11
-13
-13
-11
-7
Income Tax Expense
-1
2
0
-
-
-
-
-
-
-
Net Income
-9
-9
-10
-11
-11
-11
-13
-13
-11
-7
Net Profit Margin
-6901.42%
-5985.26%
-4883.41%
-7225.77%
-7184.85%
-7805.96%
-12324.77%
-11523.14%
-9381.67%
-2969.96%

Cardiff Oncology Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
-1
-1
0
0
0
0
0
0
0
0
Operating Income
-40
-25
-17
-16
-19
-28
-39
-45
-48
-48
EBITDA
-36
-22
-15
-15
-18
-28
-39
-45
-48
-44
Interest Expense
1
1
0
0
0
0
1
-
-
-
Depreciation
-
1
0
0
0
0
0
0
0
0
Income Before Tax
-39
-24
-16
-16
-19
-28
-38
-41
-45
-45
Income Tax Expense
0
0
0
0
0
0
-1
0
0
-
Net Income
-39
-24
-16
-16
-19
-28
-38
-41
-45
-45
Net Profit Margin
-10289.76%
-4932.08%
-4354.76%
-6709.74%
-5275.14%
-7880.50%
-10026.94%
-8492.01%
-6651.68%
-7736.26%

Cardiff Oncology Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-9
-10
-11
-11
-11
-13
-13
-11
-7
Operating Cash Flow
-7
-7
-9
-10
-10
-12
-8
-10
-5
Investing Cash Flow
13
4
14
-9
4
-14
-4
10
10
Financing Cash Flow
0
0
2
7
44
0
-
0
2
Change in Cash
6
-2
6
-12
38
-27
-13
0
7

Cardiff Oncology Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-24
-16
-16
-19
-28
-38
-41
-45
-45
Operating Cash Flow
-23
-13
-13
-16
-23
-33
-30
-37
-37
Investing Cash Flow
23
0
0
0
-131
38
36
13
1
Financing Cash Flow
-6
16
12
137
35
0
-
53
2
Change in Cash
-5
3
-1
120
-119
4
5
29
-34

Global Institutional Holdings in Cardiff Oncology Inc

Funds
Holdings
State Street Corp
1.74%
Two Sigma Investments LLC
1.06%
Candriam Luxembourg S.C.A.
0.5%
Bank of New York Mellon Corp
0.48%
Millennium Management LLC
0.28%

Insights on Cardiff Oncology Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -13.94M → -7.21M (in $), with an average increase of 39.9% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 120.0K → 243.0K (in $), with an average increase of 50.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 32.2% return, outperforming this stock by 35.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, BeOne Medicines Ltd has given 40.2% return, outperforming this stock by 79.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 year, CRDF stock has moved down by -39.7%

About Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
OrganisationCardiff Oncology Inc
Headquarters11055 Flintkote Avenue, San Diego, CA, United States, 92121
IndustryBiotechnology
CEODr. Mani Mohindru Ph.D.
E-voting on sharesClick here to vote

Key Management of Cardiff Oncology Inc

Name

Title

Dr. Mani Mohindru Ph.D.

President, CEO & Director

Dr. Roger Sidhu FRCPC, M.D.

Chief Medical Officer

Mr. Josh Muntner BFA, M.B.A.

Chief Financial Officer

Dr. Ajay Aggarwal M.B.A., M.D.

Chief Operating Officer

Ms. Brigitte Lindsay

Chief Accounting Officer

Dr. Tod Smeal Ph.D.

Chief Scientific Officer

Ms. Elizabeth Anderson

VP of Finance & Administration

FAQs

What is Cardiff Oncology Inc share price today?

Cardiff Oncology Inc share price today is $1.67 as on . Cardiff Oncology Inc share today touched a day high of $1.71 and a low of $1.64.

What is the 52 week high and 52 week low for Cardiff Oncology Inc share?

Cardiff Oncology Inc share touched a 52 week high of $4.56 on and a 52 week low of $1.48 on . Cardiff Oncology Inc stock price today i.e. is trending at $1.67,which is 63.34% down from its 52 week high and 12.84% up from its 52 week low.

What is Cardiff Oncology Inc's market capitalisation today?

Cardiff Oncology Inc market capitalisation is $0.00T as on .

How to invest in Cardiff Oncology Inc Stock (CRDF) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Cardiff Oncology Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cardiff Oncology Inc Shares that will get you 0.8982 shares as per Cardiff Oncology Inc share price of $1.67 per share as on May 13, 2026 at 10:43 pm IST.

What is the minimum amount required to buy Cardiff Oncology Inc Stock (CRDF) from India?

Indian investors can start investing in Cardiff Oncology Inc (CRDF) shares with as little as ₹95.705 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in Cardiff Oncology Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Cardiff Oncology Inc share’s latest price of $1.67 as on May 13, 2026 at 10:43 pm IST, you will get 5.9880 shares of Cardiff Oncology Inc. Learn more about fractional shares .

What are the returns that Cardiff Oncology Inc has given to Indian investors in the last 5 years?

Cardiff Oncology Inc stock has given -80.68% share price returns and 29.72% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?